Open access
Sep 2026
A small molecule ACT004 targets four-and-a-half LIM domain protein 1 to disrupt TGF-β/Smad signaling and promote FHL1 degradation in renal fibrosis.
Renal fibrosis is a common endpoint of chronic kidney disease (CKD), yet effective targeted anti-fibrotic therapies remain limited. Ovatodiolide (OVA) has anti-fibrotic activity but poor drug-like properties, whereas ACT004, a synthetic OVA derivative, has improved water solubility and metabolic stability. However, whe...
Xiao-Yang He, Fen-Fen Peng, Hui-Zhen Wang et al.
· Pharmacological Research · 0 citations